Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
19 08 2021
Historique:
received: 09 04 2021
accepted: 03 08 2021
entrez: 20 8 2021
pubmed: 21 8 2021
medline: 16 11 2021
Statut: epublish

Résumé

The spatio-temporal characteristics of grey matter (GM) impairment in multiple sclerosis (MS) are poorly understood. We used a new surface-based diffusion MRI processing tool to investigate regional modifications of microstructure, and we quantified volume loss in GM in a cohort of patients with MS classified into three groups according to disease duration. Additionally, we investigated the relationship between GM changes with disease severity. We studied 54 healthy controls and 247 MS patients classified regarding disease duration: MS1 (less than 5 years, n = 67); MS2 (5-15 years, n = 107); and MS3 (more than15 years, n = 73). We compared GM mean diffusivity (MD), fractional anisotropy (FA) and volume between groups, and estimated their clinical associations. Regional modifications in diffusion measures (MD and FA) and volume did not overlap early in the disease, and became widespread in later phases. We found higher MD in MS1 group, mainly in the temporal cortex, and volume reduction in deep GM and left precuneus. Additional MD changes were evident in cingulate and occipital cortices in the MS2 group, coupled to volume reductions in deep GM and parietal and frontal poles. Changes in MD and volume extended to more than 80% of regions in MS3 group. Conversely, increments in FA, with very low effect size, were observed in the parietal cortex and thalamus in MS1 and MS2 groups, and extended to the frontal lobe in the later group. MD and GM changes were associated with white matter lesion load and with physical and cognitive disability. Microstructural integrity loss and atrophy present differential spatial predominance early in MS and accrual over time, probably due to distinct pathogenic mechanisms that underlie tissue damage.

Identifiants

pubmed: 34413373
doi: 10.1038/s41598-021-96132-x
pii: 10.1038/s41598-021-96132-x
pmc: PMC8376987
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

16805

Subventions

Organisme : NIA NIH HHS
ID : RF1 AG061566
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG056850
Pays : United States
Organisme : NIA NIH HHS
ID : R21 AG056974
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Brain. 2017 Nov 1;140(11):2912-2926
pubmed: 29053798
Hum Brain Mapp. 2019 Oct 15;40(15):4417-4431
pubmed: 31355989
Brain. 2018 Jun 1;141(6):1665-1677
pubmed: 29741648
Neuroimage. 2019 Nov 15;202:116137
pubmed: 31473352
Neuroimage. 2004;23 Suppl 1:S208-19
pubmed: 15501092
J Neurol Neurosurg Psychiatry. 2014 Dec;85(12):1386-95
pubmed: 24899728
Neuroimage. 2011 Jun 1;56(3):907-22
pubmed: 21352927
Hum Brain Mapp. 2020 Jun 1;41(8):2198-2215
pubmed: 32067281
Mult Scler. 2014 Apr;20(4):424-32
pubmed: 24005025
Multimodal Brain Image Anal Math Found Comput Anat (2019). 2019 Oct;11846:112-120
pubmed: 33537683
Cell Mol Life Sci. 2015 Mar;72(6):1127-47
pubmed: 25417212
Front Physiol. 2020 Mar 13;11:116
pubmed: 32231581
Mult Scler. 2006 Apr;12(2):187-95
pubmed: 16629422
J Neurol Neurosurg Psychiatry. 2010 Jul;81(7):798-805
pubmed: 20392973
PLoS One. 2013 Oct 04;8(10):e75115
pubmed: 24124469
Neurol Neuroimmunol Neuroinflamm. 2018 Sep 26;5(6):e502
pubmed: 30345330
Mult Scler. 2021 Mar;27(3):380-390
pubmed: 32390507
Quant Imaging Med Surg. 2012 Dec;2(4):254-65
pubmed: 23289085
Biophys J. 1994 Jan;66(1):259-67
pubmed: 8130344
Neuroimage. 2007 Apr 1;35(2):467-77
pubmed: 17258908
Neuroimage. 2020 Sep;218:116956
pubmed: 32470572
Psychiatry Res. 2015 Dec 30;234(3):352-61
pubmed: 26602610
Nat Rev Neurosci. 2015 Mar;16(3):147-58
pubmed: 25697158
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neuroimage. 2017 Nov 1;161:149-170
pubmed: 28826946
Mult Scler. 2015 Jun;21(7):935-44
pubmed: 25392318
Mult Scler. 2016 Dec;22(14):1804-1811
pubmed: 26945031
Lancet Neurol. 2015 Mar;14(3):302-17
pubmed: 25662900
Ann Neurol. 2016 Oct;80(4):499-510
pubmed: 27464262
Neuroimage Clin. 2016 Dec 05;13:288-296
pubmed: 28050344
Neurology. 2020 Nov 3;95(18):e2565-e2576
pubmed: 32913016
Brain. 2019 Apr 1;142(4):1121-1133
pubmed: 30906945
Neuroimage. 2016 Oct 1;139:376-384
pubmed: 27377222
JAMA Neurol. 2018 Oct 1;75(10):1246-1255
pubmed: 29971335
Front Neurosci. 2012 Dec 05;6:171
pubmed: 23227001
J Neuropathol Exp Neurol. 2015 May;74(5):453-8
pubmed: 25853695
Sci Rep. 2019 Aug 22;9(1):12246
pubmed: 31439874
Alzheimers Dement. 2021 Apr;17(4):618-628
pubmed: 33196147
Hum Brain Mapp. 2018 May;39(5):2133-2146
pubmed: 29411457
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):
pubmed: 29358320
PLoS One. 2015 Sep 16;10(9):e0137064
pubmed: 26376179
Neurology. 1991 May;41(5):685-91
pubmed: 2027484
Neuroimage. 2009 Oct 15;48(1):63-72
pubmed: 19573611
Mult Scler. 2016 Feb;22(2):150-9
pubmed: 26014608
Alzheimers Dement. 2018 Mar;14(3):340-351
pubmed: 29080407
Nat Rev Neurol. 2021 Mar;17(3):173-184
pubmed: 33437067
Brain. 2019 Jul 1;142(7):1921-1937
pubmed: 31168614
N Engl J Med. 2011 Dec 8;365(23):2188-97
pubmed: 22150037
Ann Neurol. 2018 Feb;83(2):210-222
pubmed: 29331092
J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):67-75
pubmed: 23486991

Auteurs

Elisabeth Solana (E)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain. elisabeth.solana@idibaps.org.

Eloy Martinez-Heras (E)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain. emartind@clinic.cat.

Victor Montal (V)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.
Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.

Eduard Vilaplana (E)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.
Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.

Elisabet Lopez-Soley (E)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Joaquim Radua (J)

Imaging of Mood and Anxiety Related Disorders (IMARD) Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Mental Health Research Networking Center (CIBERSAM), Barcelona, Spain.
Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
Centre for Psychiatric Research and Education, Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden.

Nuria Sola-Valls (N)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Carmen Montejo (C)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Yolanda Blanco (Y)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Irene Pulido-Valdeolivas (I)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Maria Sepúlveda (M)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Magi Andorra (M)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Joan Berenguer (J)

Neuroradiology Section, Radiology Service of the Image Diagnosis Center of the Hospital Clinic de Barcelona, Barcelona, Spain.

Pablo Villoslada (P)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

E H Martinez-Lapiscina (EH)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Ferran Prados (F)

E-health Centre, Universitat Oberta de Catalunya, Barcelona, Spain.
Centre for Medical Image Computing (CMIC), Department of Medical Physics and Bioengineering, University College London, London, UK.
NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK.

Albert Saiz (A)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Juan Fortea (J)

Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain.
Centro de Investigacion Biomedica en Red de Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.

Sara Llufriu (S)

Center of Neuroimmunology, Laboratory of Advanced Imaging in Neuroimmunological Diseases, Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Universitat de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH